The Early Access Committee Announces an Additional Site for Radium-223 Chloride (Alpharadin) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases

We have been able to get Bayer to open another early access site for Alpharedin. This additional site is in Boston, Ma. In addition to this new site there are still three other sites.

This trial will have no placebo and there will not be any cost for the Alpharadin. In certain cirmustances there might be some costs. So check with the site prior to beginning the therapy.

Basic Eligibility Criteria:
• CRPC/HRPC – on hormone therapy with progressive disease
• At least 2 bone metastases – blastic (sclerotic), not lytic
• Some amount of pain/bone pain (must be taking daily meds – even if it’s Tylenol)
• No mets to lung, liver, or brain
• HGB 10.0 or higher
• Previously treated with Taxotere (or have refused Taxotere – patient’s choice)
• 4 weeks since chemo, and No chemo currently planned
• No abiraterone (Zytiga) while on Alpharadin – previous OK
• No previous extensive radiation to bone (> 25% of bone marrow), and No previous Quadramet or Strontium 89

If you think you fit this Basic Eligibility Criteria, contact one of the sites below for further screening.

Stanford University
Contact: Euodia Jonathan, (prefers EMAIL), or (650) 723-7419
Stanford, CA 94305

Moffitt Cancer Center
Contact: Bonnie Sauder, RN (813) 745-3574 or
Tampa, FL 33612

Tulane University
Contact: Patrick Cotogno (504) 988-6542 or
New Orleans, LA 70112

Mass General Hospital
Boston, MA
Contact: Carol or Kara (617) 724-5257

Comprehensive Cancer Ctrs of Nevada
Las Vegas, NV 89169
Contact: Victoria Le (702) 952-340 or

Alpharadin is a systemic treatment for bone mets when a patient can not have any additional radiation or when there are multiple tumor sites.

Joel T Nowak, M.A., M.S.W.